Genomic Biomarker Market Forecast Reveals Where Future Industry Value Will Be Created
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Genomic Biomarker Market Revenue Outlook: What CAGR Is Expected Through 2030?
The genomic biomarker market has seen significant expansion in recent years, increasing from $9.9 billion in 2025 to an anticipated $11.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.8%. This historic growth is driven by rising investments in genomic research, the broadening of biomarker studies centered on oncology, greater access to next-generation sequencing tools, stronger partnerships between diagnostics and pharmaceutical firms, and the early uptake of personalized medicine strategies.
The genomic biomarker market is anticipated to experience rapid expansion over the coming years, reaching $22.23 billion by 2030 with a compound annual growth rate (CAGR) of 17.5%. This projected growth during the forecast period is driven by factors such as the rising demand for precision medicine therapies, an increased application of biomarkers in drug development, broader adoption of companion diagnostics, a greater emphasis on early disease detection, and enhanced regulatory support for biomarker-based approvals. Key trends shaping this period include the growing utilization of predictive genomic biomarkers, the expanding use of pharmacogenomic testing, the increasing incorporation of genomic data into clinical decision-making, the broadening of biomarker-based oncology diagnostics, and a stronger focus on clinical validation standards.
Download A Free Sample Report For Comprehensive Market Insights:
Genomic Biomarker Market Expansion Supported By Key Demand Factors
The growing incidence of chronic conditions is set to drive forward the expansion of the genomic biomarker market in the coming period. Chronic diseases represent persistent health issues that last over extended durations and typically develop at a gradual pace. Their increasing frequency can be attributed to aging demographics and a climbing prevalence of lifestyle-linked disorders including obesity and diabetes. Through the identification of genetic susceptibilities and the customization of medical strategies, genomic biomarkers facilitate early detection along with individualized preventive approaches for managing these long-term illnesses. Such a forward-looking methodology works to curb overall prevalence figures by directing attention toward individuals showing heightened risk before the actual manifestation of disease. As an illustrative point, data from the World Health Organization, an intergovernmental body operating out of Switzerland, indicated in September 2023 that 41 million deaths occur globally on an annual basis, with those fatalities linked to chronic diseases accounting for a substantial 74 percent of all deaths. Among this total, cardiovascular conditions claim 17.9 million lives annually, cancer is responsible for 9.3 million deaths, chronic respiratory diseases contribute 4.1 million fatalities, and diabetes accounts for 2.0 million deaths each year. Consequently, it is the mounting frequency of these persistent health conditions that serves as a primary catalyst for advancement within the genomic biomarker sector.
Genomic Biomarker Market Segmentation And Category Breakdown
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
Genomic Biomarker Market Growth Trends Influencing Competitive Dynamics
Leading players in the genomic biomarker space are concentrating on creating sophisticated tools like next-generation liquid biopsy assays to allow thorough genomic mapping of solid tumors. A liquid biopsy assay refers to a diagnostic method that examines genetic material—mainly circulating tumor DNA (ctDNA)—extracted from a blood sample to identify and track cancer. The detection of genomic biomarkers can reveal details regarding particular mutations, gene expression patterns, or other genetic changes linked to cancer. As an example, in November 2023, Illumina Inc., a biotechnology firm based in the United States, introduced the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), an advanced liquid biopsy assay designed for comprehensive genomic profiling of solid tumors. This assay boasts improved analytical sensitivity, capable of identifying low-frequency variants using only 20 ng of cell-free DNA, a reduction from the previous 30 ng. Results are available in less than four days, which significantly speeds up genomic profiling relative to conventional approaches. The simplified workflow along with upcoming automation is expected to facilitate laboratory integration and enhance operational efficiency.
Genomic Biomarker Market Competitive Analysis Of Major Industry Participants
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
Access The Complete Genomic Biomarker Market Report:
Genomic Biomarker Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
